Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has received a consensus recommendation of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $3.33.

Several research firms recently commented on SYRS. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday. Finally, StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 4th.

Syros Pharmaceuticals Trading Down 5.7 %

Shares of SYRS opened at $0.26 on Wednesday. The stock’s 50-day moving average is $2.02 and its two-hundred day moving average is $3.79. The stock has a market cap of $6.96 million, a PE ratio of -0.09 and a beta of 1.59. Syros Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $8.17. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) EPS. Equities analysts forecast that Syros Pharmaceuticals will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Syros Pharmaceuticals

In related news, CEO Conley Chee bought 50,000 shares of the stock in a transaction dated Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the completion of the acquisition, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jason Haas acquired 35,363 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average cost of $1.55 per share, with a total value of $54,812.65. Following the completion of the acquisition, the chief financial officer now directly owns 59,915 shares in the company, valued at approximately $92,868.25. This represents a 144.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 130,707 shares of company stock worth $206,491 over the last quarter. 12.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new position in Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Virtu Financial LLC bought a new position in Syros Pharmaceuticals during the 1st quarter valued at $64,000. Acadian Asset Management LLC bought a new position in Syros Pharmaceuticals during the 1st quarter valued at $91,000. Certuity LLC bought a new position in Syros Pharmaceuticals during the 2nd quarter valued at $109,000. Finally, Kennedy Capital Management LLC bought a new position in Syros Pharmaceuticals during the 1st quarter valued at $2,166,000. 91.47% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.